Qiming Venture Partners

🔊 Looking back, what Qiming Venture Partners has achieved? Find out more in 60 seconds.

Congratulations to three of our portfolio companies for being recognized in the 2024 Fortune China's Most Admired Companies All-Stars and Industry Stars Lists! Xiaomi Technology (SEHK: 1810) and Meituan (SEHK: 3690) earned spots on the All-Stars List, while WeRide (NASDAQ: WRD) was featured on the Industry Stars List. The All-Stars List was determined through a comprehensive survey of business leaders, assessing companies across all industries to identify their most admired companies. The Industry Stars List evaluates factors such as management, talent attraction, product/service quality, social responsibility, investment value, and globalization. #FortuneChina #MostAdmiredCompanies #Innovation #Leadership #BusinessExcellence #VentureCapital #ChineseTech #QimingPortfolio

Our portfolio company moodytiger is partnering with UNICEF HK to support this year's UNICEF Charity Run – one of Hong Kong's largest charity road races, now in its 16th year! The 2024 event, themed "HERO RUN," calls on everyone to step up as heroes for children's health and well-being. With a target of 16,300 runners and a two-day program (including HERO RUN – WondeRun and HERO RUN – PoweRun), this race is dedicated to UNICEF's impactful work across more than 190 countries and regions, funding critical initiatives in nutrition, clean water, sanitation, and child rights. This year marks the third year of collaboration between moodytiger and UNICEF HK. As the official sportswear of the event, moodytiger will not only provide breathable, quick-dry, lightweight T-shirts for each runner, but also gift an additional pair of race leggings for children participating in the WondeRun. #UNICEFCharityRun #HERO_RUN #UNICEFHK #ForEveryChild #RunForGood #QimingPortfolioESG #QimingConsumer

Our portfolio company, MedSci (SEHK: 2415), has introduced its Digital Precision Promotion Solution. This cutting-edge solution demonstrates how digital technology can create competitive advantages while enhancing brand marketing effectiveness and reducing costs. Built on MedSci's extensive network of registered physicians, this solution utilizes precise omnichannel marketing techniques to effectively deliver product information and promotional content to target physicians and other audiences. MedSci currently boasts approximately 3.1 million registered physicians, with an average of about 2.9 million active users per month in 2024. This substantial user base provides strong support for digital precision promotion. The solution is versatile and adaptable to various stages of a product's lifecycle, achieving different objectives based on specific goals. Central to the Digital Precision Promotion Solution is its robust data analysis and targeted delivery capabilities. MedSci conducts deep analysis of physician user behavior patterns and preferences to create accurate user profiles. Based on these profiles, MedSci provides customized promotion strategies, ensuring that information is distributed accurately and efficiently to the target audience. #DigitalHealth #PrecisionMedicine #HealthcareInnovation #BrandMarketing #MedicalData #DigitalTransformation #HealthcareQuality #QimingPortfolio #QimingHealthcare

Sunyur Network has partnered with MENGNIU Dairy Co., ltd., one of China's leading dairy companies. This collaboration aims to create an intelligent procurement platform that enhances procurement productivity and delivers greater value to the enterprise. Sunyur specializes in digital procurement solutions for medium to large enterprises. Through its intelligent procurement platform, Air SaaS applications, Pro Suite package, and operational services, Sunyur empowers clients to build customized online procurement platforms. This initiative enables companies to digitize and streamline their entire procurement process, resulting in improved efficiency and reduced costs. #DigitalProcurement #Innovation #SmartProcurement #MRO #Ecommerce #Efficiency #CostReduction #QimingPortfolio #QimingTechnology

At the Global Health Exhibition 2024, ET Healthcare showcased its Pylon 3D system. This year, the company has expanded its global presence with exhibitions in Dubai, UAE, Da Nang, Vietnam, Bangkok, Thailand, Chicago, USA, and Riyadh, Saudi Arabia. The Pylon 3D fully automated immunoassay system revolutionizes blood testing by simplifying the process with a single needle. It ensures precision throughout the entire analysis, meeting international laboratory standards. The system supports various sample types, including whole blood, plasma, and serum, and features a micro-sample mode specifically designed to address pediatric testing challenges. Additionally, its innovative no-liquid-flow detection technology makes operation easy and maintenance straightforward, all while occupying minimal space for flexible placement. #Pylon3D #GlobalHealthExhibition #Innovation #Immunoassay #HealthcareTechnology #MedTech #InternationalExpansion #LaboratoryStandards #QimingPortfolio #QimingHealthcare

Collaborating with the Intelligent Imaging Processing and Analysis Laboratory at Fuzhou University and the School of Data Science at Fudan University, Infervision recently published an article in the prestigious IEEE Transactions on Medical Imaging (TMI), which boasts an impressive impact factor of 10.6. This research highlights Infervision's innovative developments in medical image segmentation algorithms and reinforces the solid technical foundation of its AI products, enhancing their generalization capabilities, stability, and accuracy. Addressing a longstanding challenge in the field, this study proposes a multi-source unsupervised domain adaptation (MUDA) method. This approach effectively mitigates issues caused by domain shifts due to variations in hospitals, imaging devices, and operators, which can significantly affect model performance. Infervision's AI solutions are now deployed in around 30 countries and regions, demonstrating their ability to adapt to diverse clinical environments and ensuring reliable diagnostic results. #MedicalImaging #Research #Innovation #MachineLearning #IEEE #TMI #DomainAdaptation #ClinicalExcellence #QimingPortfolio #QimingHealthcare

Dr. Shijie Ding, CEO of Joes Future Food, recently delivered a keynote at the China International Food Safety & Quality Conference (CIFSQ), sharing insights on advancements in cell-cultured pork technology and pilot-scale production. His presentation highlighted the pioneering work led by Professor Guanghong Zhou's team at Nanjing Agricultural University, which began in 2009 and led to the creation of China's first cultured meat. Dr. Shijie Ding discussed significant breakthroughs in scaling lab research to pilot production, including innovations in culture media optimization and bioreactor technology to improve fat and protein differentiation. With over a decade of technological development, cultured meat production now has a solid foundation, setting the stage for efficient, large-scale production in the future. #CulturedMeat #FoodTech #SustainableProtein #Innovation #FoodSafety #CIFSQ #FutureOfFood #CellularAgriculture #Biotechnology #QimingPortfolio #QimingHealthcare

M20 Genomics has announced a major upgrade to its M20 Spatial technology. This latest release features a proprietary chip along with optimized functions across multiple dimensions, delivering substantial improvements in gene detection sensitivity, resolution, and data analysis. This upgrade provides researchers with access to even more precise, high-resolution spatial multi-omics data while retaining key capabilities such as multi-species compatibility, whole-sample processing, and full-transcriptome coverage. Since its launch in October 2023, M20 Spatial has become a valuable tool in spatial biology research. This latest iteration offers enhanced sensitivity, improved resolution, and deeper analytical capabilities, broadening its applications in biopharmaceutical research and life sciences. #SpatialTranscriptomics #MultiOmics #Biopharma #GeneDetection #SpatialBiology #LifeSciences #Innovation #QimingPortfolio #QimingHealthcare

MEDx has received approval from China's NMPA for its PD-L1 (JS311) antibody reagent, developed in collaboration with Shanghai Junshi Biosciences Co Ltd. This marks the first companion diagnostic kit approved by the NMPA for use in patients with triple-negative breast cancer (TNBC). This innovative kit enables the detection of PD-L1 protein expression in tumor tissues, serving as a companion diagnostic for Toripalimab. MEDx has also successfully completed comprehensive laboratory and clinical validations to ensure the precision, accuracy, specificity, and reproducibility of the reagent. The partnership between Junshi Biosciences and MEDx establishes a new standard for first-line treatment in PD-L1 positive recurrent or metastatic TNBC patients, further advancing personalized cancer therapy. #CancerTherapy #PersonalizedMedicine #ImmunoOncology #ClinicalInnovation #NMPA #TNBC #QimingPortfolio #QimingHealthcare